Overview

* Gossamer Bio ( GOSS ) Q2 revenue drops to $11.5 mln from $95.8 mln yr/yr

* Net loss for Q2 2025 at $38.3 mln, impacted by absence of one-time license revenue

* Topline results from Phase 3 PROSERA Study expected in February 2026

Outlook

* Gossamer Bio ( GOSS ) expects topline PROSERA Study results in February 2026

* Company plans first site activations for SERANATA Study in Q4 2025

* Gossamer Bio ( GOSS ) expects cash reserves to fund operations into 2027

Result Drivers

* REVENUE DECLINE - Co attributes revenue drop to absence of one-time license revenue from collaboration with Chiesi

* CLINICAL TRIALS - Completion of enrollment for Phase 3 PROSERA Study in PAH patients

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.17

Q2 Net -$38.27

Income mln

Q2 Basic -$0.17

EPS

Q2 $50.25

Operatin mln

g

Expenses

Q2 -$38.76

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Gossamer Bio Inc ( GOSS ) is $8.00, about 72.9% above its August 4 closing price of $2.17

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)